| Primary |
| Kawasaki's Disease |
16.4% |
| Off Label Use |
16.4% |
| Hypogammaglobulinaemia |
9.2% |
| Product Used For Unknown Indication |
7.2% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
5.3% |
| Immunodeficiency Common Variable |
5.3% |
| Myasthenia Gravis |
5.3% |
| Polymyositis |
5.3% |
| Drug Use For Unknown Indication |
3.9% |
| Immunodeficiency |
3.9% |
| Asthma |
2.6% |
| Bruton's Agammaglobulinaemia |
2.6% |
| Immunoglobulins Decreased |
2.6% |
| Polyneuropathy |
2.6% |
| Dementia Alzheimer's Type |
2.0% |
| Depression |
2.0% |
| Guillain-barre Syndrome |
2.0% |
| Idiopathic Thrombocytopenic Purpura |
2.0% |
| Selective Igg Subclass Deficiency |
2.0% |
| Bone Marrow Failure |
1.3% |
|
| Therapeutic Product Ineffective For Unapproved Indication |
23.1% |
| Pyrexia |
11.5% |
| Urticaria |
7.7% |
| Vomiting |
6.7% |
| Hepatitis C |
4.8% |
| Infusion Related Reaction |
4.8% |
| Rash |
4.8% |
| Tremor |
4.8% |
| Death |
3.8% |
| Hepatitis |
3.8% |
| Pharmaceutical Product Complaint |
3.8% |
| Dyspnoea |
2.9% |
| Headache |
2.9% |
| Meningitis Aseptic |
2.9% |
| Blood Pressure Decreased |
1.9% |
| Chills |
1.9% |
| Drug Effect Decreased |
1.9% |
| Haemolytic Anaemia |
1.9% |
| Hypotension |
1.9% |
| Ill-defined Disorder |
1.9% |
|
| Secondary |
| Asthma |
37.4% |
| Drug Use For Unknown Indication |
19.5% |
| Infection Prophylaxis |
18.7% |
| Off Label Use |
6.5% |
| Dermatomyositis |
2.1% |
| Selective Igg Subclass Deficiency |
2.1% |
| Vasculitis |
1.8% |
| Idiopathic Thrombocytopenic Purpura |
1.6% |
| Primary Immunodeficiency Syndrome |
1.6% |
| Hypogammaglobulinaemia |
1.0% |
| Premedication |
1.0% |
| Product Used For Unknown Indication |
1.0% |
| Common Variable Immunodeficiency |
0.8% |
| Hypogammaglobulinemia |
0.8% |
| Kawasaki's Disease |
0.8% |
| Myasthenia Gravis |
0.8% |
| Necrotising Fasciitis |
0.8% |
| Polymyositis |
0.8% |
| Allergenic Desensitisation Procedure |
0.5% |
| Blood Immunoglobulin G Decreased |
0.5% |
|
| Hepatitis C |
58.4% |
| Therapeutic Product Ineffective For Unapproved Indication |
17.5% |
| Haemolytic Anaemia |
2.2% |
| Infusion Related Reaction |
2.2% |
| Pharmaceutical Product Complaint |
2.2% |
| Hypersensitivity |
1.5% |
| Ill-defined Disorder |
1.5% |
| Meningitis |
1.5% |
| Meningitis Aseptic |
1.5% |
| Post Procedural Infection |
1.5% |
| Rash |
1.5% |
| Rash Macular |
1.5% |
| Tremor |
1.5% |
| Vomiting |
1.5% |
| Cough |
0.7% |
| Drug Ineffective |
0.7% |
| Erythema |
0.7% |
| Haemolytic Transfusion Reaction |
0.7% |
| Mobility Decreased |
0.7% |
| Nausea |
0.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.6% |
| Drug Use For Unknown Indication |
11.9% |
| Allogenic Bone Marrow Transplantation Therapy |
7.9% |
| Immunosuppression |
7.2% |
| Immunosuppressant Drug Therapy |
5.0% |
| Asthma |
4.0% |
| Multiple Myeloma |
3.7% |
| Pain |
3.7% |
| Prophylaxis Against Transplant Rejection |
3.7% |
| Multiple Sclerosis |
3.0% |
| Hypertension |
2.5% |
| Prophylaxis |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.5% |
| Pneumonia |
1.5% |
| Diabetes Mellitus |
1.2% |
| Antiviral Prophylaxis |
1.0% |
| Anxiety |
1.0% |
| Aplasia Pure Red Cell |
1.0% |
| Bronchitis |
1.0% |
| Cytomegalovirus Infection |
1.0% |
|
| Weight Decreased |
11.5% |
| Cardiac Failure |
7.7% |
| Diarrhoea |
7.7% |
| Platelet Count Decreased |
5.8% |
| Sepsis |
5.8% |
| Stomatitis |
5.8% |
| White Blood Cell Count Decreased |
5.8% |
| Acute Respiratory Distress Syndrome |
3.8% |
| Arrhythmia |
3.8% |
| Blood Cholesterol Increased |
3.8% |
| Fatigue |
3.8% |
| Haemorrhage Intracranial |
3.8% |
| Loss Of Consciousness |
3.8% |
| Osteoarthritis |
3.8% |
| Pneumonia |
3.8% |
| Progressive Multifocal Leukoencephalopathy |
3.8% |
| Pruritus |
3.8% |
| Rash |
3.8% |
| Renal Impairment |
3.8% |
| Septic Shock |
3.8% |
|
| Interacting |
|
|
